Literature DB >> 1626489

Reflex cardiovascular control in congestive heart failure.

G Mancia1, G Seravalle, C Giannattasio, M Bossi, L Preti, B M Cattaneo, G Grassi.   

Abstract

This article reviews evidence that the reflex control of the cardiovascular system provided by negative feedback mechanisms is impaired in congestive heart failure (CHF). The impairment involves vagal and sympathetic modulation of the heart exerted by arterial baroreceptors. It also affects baroreceptor control of blood pressure and peripheral vascular resistance, as well as the cardiopulmonary receptor's ability to modulate sympathetic activity. The degree of such impairment is most marked in severe CHF but is also apparent, to a minor degree, in mild heart failure. Reflex impairment is due to a reduction in the receptor signal, but other factor under investigation are probably also involved. Digoxin and other pharmacologic treatments of CHF improve reflex function, thereby facilitating a reduction in the elevated sympathetic activity and a stepping up of the reduced vagal activity typical of CHF. This may be relevant to a patient's prognosis.

Entities:  

Mesh:

Year:  1992        PMID: 1626489     DOI: 10.1016/0002-9149(92)91251-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure.

Authors:  Hani N Sabbah; Ramesh C Gupta; Makoto Imai; Eric D Irwin; Sharad Rastogi; Martin A Rossing; Robert S Kieval
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

Review 2.  Central mechanisms for exercise training-induced reduction in sympatho-excitation in chronic heart failure.

Authors:  Karla K V Haack; Irving H Zucker
Journal:  Auton Neurosci       Date:  2014-10-18       Impact factor: 3.145

Review 3.  The control of adrenergic function in heart failure: therapeutic intervention.

Authors:  A L Clark; J G Cleland
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 4.  Angiotensin II--nitric oxide interactions in the control of sympathetic outflow in heart failure.

Authors:  I H Zucker; J L Liu
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

5.  Open-loop dynamic and static characteristics of the carotid sinus baroreflex in rats with chronic heart failure after myocardial infarction.

Authors:  Toru Kawada; Meihua Li; Atsunori Kamiya; Shuji Shimizu; Kazunori Uemura; Hiromi Yamamoto; Masaru Sugimachi
Journal:  J Physiol Sci       Date:  2010-06-01       Impact factor: 2.781

6.  Abnormal baroreflex function is dissociated from central angiotensin II receptor expression in chronic heart failure.

Authors:  Mohammad Fahim; Lie Gao; Tarek M Mousa; Dongmei Liu; Kurtis G Cornish; Irving H Zucker
Journal:  Shock       Date:  2012-03       Impact factor: 3.454

7.  Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT1 receptors in heart failure.

Authors:  Wei-Zhong Wang; Lie Gao; Han-Jun Wang; Irving H Zucker; Wei Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

8.  NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits.

Authors:  Yu-Long Li; Lie Gao; Irving H Zucker; Harold D Schultz
Journal:  Cardiovasc Res       Date:  2007-04-19       Impact factor: 10.787

Review 9.  Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction.

Authors:  Edoardo Gronda; Darrel Francis; Faiez Zannad; Christian Hamm; Josep Brugada; Emilio Vanoli
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2017-09       Impact factor: 2.160

Review 10.  Carvedilol in the treatment of elderly patients with chronic heart failure.

Authors:  Klaus K A Witte; Andrew L Clark
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.